de Heus RAA, et al. - Researchers used data from A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer’s Disease to evaluate if cognitive and functional decline in Alzheimer disease could be predicted by blood pressure (BP) variability (BPV). This study included patients with mild-to-moderate Alzheimer disease and ≥ 3 office BP measurements. They evaluated day-to-day BPV in a subsample, using home BP measurements. Participants were 460 in total, aged 72.1 years, with mean BP of 134.0/75.1 (10.9/6.3) mmHg. Greater deterioration on Alzheimer’s Disease Assessment Scale–cognitive subscale was seen in the highest quartile of BPV vs the lowest quartile, following 1 year. This link was still present after 1.5 years. According to findings from this post hoc analysis, there may be an association of higher visit-to-visit and day-to-day BPV with progression of Alzheimer disease. A future target may be targeting BPV to slow decline in patients with Alzheimer disease.